China PharmaHub Signs Agreement with Chengdu Yongkon Pharmacy

BOSTON, Aug. 18 /PRNewswire/ -- China PharmaHub Corp. ("PharmaHub"), recently merged with World Wide Relics (OTC Bulletin Board: WRLC), which will be shortly changing its name to China PharmaHub Corp, is proud to announce it has signed a cooperation agreement with Chengdu Yongkon Pharmacy Co. Ltd., ("Yongkon"), a pharmaceutical company based in Sichuan, with an established sales network of over 2600 hospitals in China.  PharmaHub was authorized by Yongkon as its appointed agent to identify pharmaceutical products and medical devices in the U.S. and negotiate the terms to obtain the rights to sell such products and devices in China.

Yongkon is an established and GMP certified pharmaceutical company with focus on the identification, development, manufacture, sales and distribution of Chinese traditional medicine, biopharmaceuticals and medical equipment with its focus on antiviral drugs, bio-engineering drugs and anticancer drugs.  Yongkon manufactures and sells over 90 GMP approved drugs in China. Its leading product, Xiaojinwan, is a well known Traditional Chinese Medicine treating breast hyperplasia, thyroid and benign tumor.  Yongkon has a marketing force of over 400 sales personnel in 34 sales offices in over 31 provinces and cities as well as in Beijing, Tianjin, Shanghai and Chongqing.  

Richard Lui, CEO of PharmaHub, said "We are glad to gain another capable strategic partner in China. In less than one year of founding, we have successfully established partnerships with Research Institute and Government Agencies in China. We have now taken an important step in the partnership with entrepreneurs.  With the accomplishment of this major milestone, we've successfully created a chain of command in the commercialization of technologies we identify and bring to China.  Yongkon supports our structure with an established sales and marketing team and nationwide sales channel."

Lui continued, "This is another successful demonstration of our HUB model, of partnering with successful enterprises and working together to bring life saving pharmaceuticals and medical devices to the world.  PharmaHub's relationships with the New Drug Center and the Sichuan Technical Exchange Center, and now with Chengdu Yongkon, represent PharmaHub's drive to become  an innovator in the pharmaceutical and medical device industry."

About PharmaHub:

China PharmaHub Corp. is engaged in the business of licensing, developing and the commercialization of pharmaceutical and healthcare products and technologies between Chinese pharmaceutical companies and other pharmaceutical companies located worldwide, with initial emphasis in the United States and Europe. Management believes that PharmaHub brings a unique wealth of resources to assist scientists and companies in bringing their ideas to reality.  PharmaHub's corporate headquarters are located in California, with offices in Boston and China. For more information visit www.chnpharmahub.com .

Forward-Looking Statements

This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Except as otherwise required by the federal securities laws, the Company disclaims any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein.

SOURCE China PharmaHub Corp.